<DOC>
	<DOCNO>NCT01679587</DOCNO>
	<brief_summary>Primary objective ass subject CKD : Safety tolerability molidustat ( BAY 85-3934 ) , effect molidustat non-invasive hemodynamics Secondary objective ass : Effects pharmacodynamic parameter erythropoiesis ( erythropoietin , reticulocytes , erythrocyte , hemoglobin , hematocrit ) , pharmacokinetics molidustat , exploratory biomarkers , ie , midregional pro-atrial natriuretic peptide , midregional pro-adrenomedullin , plasma renin activity , optionally B-type natriuretic peptide , vascular endothelial growth factor , cyclic guanosine monophosphate , cyclic adenosine monophosphate , noradrenaline</brief_summary>
	<brief_title>Dose Escalation Study Investigate Safety , Tolerability , Pharmacodynamics , Pharmacokinetics BAY85-3934 Subjects With Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Presence chronic kidney disease ( CKD ) dialysis assess medical history eGFR ( MDRD ) = &lt; 60 mL/min estimate prestudy visit Stable renal disease , ie expect begin dialysis study Systolic blood pressure = &gt; 110 mmHg = &lt; 160 mmHg Heart rate = &lt; 100 BPM Hemoglobin = &gt; 9 g/dL Female subject without childbearing potential , ie postmenopausal woman 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 30 mIU/mL , woman 6 week post bilateral ovariectomy , woman bilateral tubal ligation , woman hysterectomy Body mass index ( BMI ) : = &gt; 18 = &lt; 35 kg/m2 prestudy visit Incompletely cure preexist disease relevant impairment absorption , distribution , metabolism , elimination effect study drug assume Known hypersensitivity study drug ( active substance excipients preparation ) Known severe allergy , nonallergic drug reaction , multiple drug allergy Chronic heart failure , New York Heart Association ( NYHA ) IIIIV Coronary artery disease uncured significant stenosis Angina pectoris Significant stenosis cerebral vessel Significant uncorrected rhythm conduction disturbance second thirddegree atrioventricular block without cardiac pacemaker episode sustain ventricular tachycardia Subjects impair liver function ( Child Pugh B C base medical history ) History thrombotic thromboembolic event ( eg myocardial infarction , stroke , transient ischemic attack , deep vein thrombosis , pulmonary embolism ) within recent 6 month Proliferative choroidal retinal disease , neovascular agerelated macular degeneration proliferative diabetic retinopathy require likely require treatment ( intraocular injection laser photocoagulation ) study Subjects history malignant disease last 5 year Treatment EPOstimulating agent ( ESA ) rhEPO within last 2 week first intake study drug Suspicion drug alcohol abuse Positive result hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) , human immune deficiency virus antibody ( antiHIV 1+2 ) prestudy visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>